Atorvastatin For Elderly Patients With Paroxysmal Atrialfibrillation Recurrence Rate After Dual-chamber Pacemakers

Background Atrial fibrillation (Atrial fibrillation, AF) is the most common tachyarrhythmia, often leads to heart failure and thromboembolism, will increase the mortality and morbidity, the same, paroxysmal atrial fibrillation (paroxysmal atrial fibrillation, PAF) will increase mortality and morbidity, often leading to shock. A large number of domestic and foreign studies confirm that prevent and reduce the onset of PAF can effectively prevent the occurrence of cardiovascular events, how to reduce the incidence of PAF become a research hotspot. In recent years, inflammation in the pathogenesis of atrial fibrillation has been widely distributed attention. A large number of studies have shown that lipid-lowering statins in addition to the role, but still recognized the anti-atherosclerotic drugs moving, and there is a clear anti-inflammatory effects.This study by the installation of dual-chamber pacemaker in elderly postoperative patients with pacemakers programmed approach to objective and accurate evaluation of atorvastatin on the PAF have a preventive role. For the clinical treatment of PAF to provide a basis, PAF patients can also enable more treatment to reduce the onset of PAF.Objective To investigate atorvastatin effectiveness of paroxysmal atrial fibrillation in the elderly.Methods Selected2007-201OAn Zhen Hospital, installed in the PAF after dual chamber pacemaker in elderly patients100cases. Inclusion criteria:(1)60years≤aged≤80yearss(2) NYHA class<Ⅲ cardiac function (3) paroxysmal atrial fibrillation (PAF) patients. Exclusion criteria:(1) permanent AF;(2) hypertrophic cardiomyopathy;(3) combined with rheumatic heart disease;(4) statin drugs;(5), liver and kidney dysfunctionRandomly (6) Need to take antiarrhythmic drugs.divided into two groups of50patients. Check the blood, liver, kidney function, blood lipids and CRP. in the latter group received conventional therapy plus placebo1/d, as control group; the other group received conventional therapy plus atorvastatin20mg/d, is set to the test group. Take12months. Observed in patients3months,6months,9months,12months, the number of episodes of atrial fibrillation, the total duration. CRP. AF burden and Efficient.Result Compared with the control group, experimental group of12months had significantly fewer episodes of atrial fibrillation (11.5±4.3times/year vs.17.2±5.4times/year, p<0.01), total duration was significantly shorter (60.9±2.1h/y vs.81.2±3.5h/y, P p<0.01), atrial fibrillation load test group than the control group was significantly lower (0.63h/day vs.0.79h/day, p<0.01). Baseline CRP levels were enrolled in the two groups no difference, but the follow-up test at12months than in the control group, CRP levels were significantly lower (7.35±1.15mg/L vs.9.39±1.05mg/L, p<0.01). Test group and control group (30%c vs.18%), a statistically significant difference (p<0.01). Conclusion Atorvastatin statins can significantly reduce the PAF in patients with atrial fibrillation attack, which may be related with the anti-inflammatory effect of atorvastatin’s. The specific mechanism remains to be studied further.